Gilead Sciences (NASDAQ:GILD) witnessed a selling pressure and the shares last traded with a loss of -1.32 points or -1.54% at $84.45. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $11.81 million with an inflow of $134.72 million in upticks and an outflow of $122.91 million in downticks. Using the data, the up/down ratio is found to be 1.1. The share price has recorded -1.97% on a weekly basis.A block trade of $36.69 million in uptick and $24.21 million in downtick was also observed, resulting in an up/down ratio of 1.52. The net money flow of the block trade stood at a $12.48, signaling heavy buying.
Currently the company Insiders own 1.4% of Gilead Sciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.2% . Institutional Investors own 81.8% of Gilead Sciences shares. During last six month period, the net percent change held by insiders has seen a change of -9.29%. On the companys insider trading activities, Milligan John F, director officer (President and CEO) of Gilead Sciences Inc, unloaded 112,000 shares at an average price of $86.92 on June 6, 2016. The total amount of the transaction was worth $9,735,040, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Gilead Sciences (NASDAQ:GILD) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.47 points or 0.56% at $83.98 with 8,194,059 shares getting traded. Post opening the session at $84.03, the shares hit an intraday low of $83.9 and an intraday high of $84.81 and the price was in this range throughout the day. The company has a market cap of $111,846 million and the number of outstanding shares have been calculated to be 1,331,821,510 shares. The 52-week high of Gilead Sciences (NASDAQ:GILD) is $123.37 and the 52-week low is $81.28.
Many analysts have stated their opinion on the company shares. Gabelli & Co initiates coverage on Gilead Sciences (NASDAQ:GILD) The shares have been rated Buy. The rating by the firm was issued on June 1, 2016.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.